This site is intended for health professionals only

Published on 6 August 2007

Share this story:

UK’s NICE talks down abatacept


The UK’s National Institute for Clinical Excellence (NICE) has recommended against using abatacept (Orencia®) to treat people with rheumatoid arthritis, stating that it would not be a cost-effective use of NHS resources. The committee noted in its appraisal consultation document that there were no direct head-to-head comparisons of abatacept with alternative conventional DMARD regimens, TNF blockers or rituximab. The closing date for comments is 23 August 2007 and the second appraisal committee meeting will take place on 12 September 2007.

National Electronic Library for Medicines 2/8/2007


Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: